13F Holdings
中文EN

NEOG NEOGEN CORP

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 711377 · Fiscal year ends 05/31

Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.3%
TTM net income YoY94.6%
TTM EPS YoY94.6%
Revenue 3-yr CAGR-1.3%
Net income 3-yr CAGR—

Margins

Gross margin47.4%
Operating margin-0.8%
Net margin-6.3%
FCF margin5.6%
EBITDA margin12.3%

Returns

ROE-2.7%
ROA-1.7%
ROIC (approx.)-0.2%
Asset turnover0.26x

Leverage & solvency

Liabilities / assets36.8%
Debt / equity0.74x
Current ratio3.90x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-1.52x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue4.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-05-31FY20252025-05-31FY20242024-05-31FY20232023-05-31FY20222022-05-31
Income statement
Revenue$870.40M$894.66M$924.20M$822.45M$527.16M
Cost of revenue$461.90M$473.30M$460.30M$416.49M$284.15M
Gross profit$408.50M$421.40M$463.90M$405.95M$243.01M
R&D expense$18.40M$21.10M$22.50M$26.04M$17.05M
SG&A expense$245.10M$218.20M$199.90M$201.18M$82.74M
Operating income-$21.60M-$1.06B$58.60M$37.52M$58.62M
Interest expense$24.10M$38.10M$42.15M$27.25M—
Pretax income-$9.00M-$1.13B-$14.30M-$22.04M$60.21M
Income tax-$1.10M-$41.10M-$4.90M$828,000$11.90M
Net income-$7.90M-$1.09B-$9.40M-$22.87M$48.31M
EBITDA$94.70M-$941.50M$175.30M$125.89M$82.31M
EPS (basic)-0.04-5.03-0.04-0.120.45
EPS (diluted)-0.04-5.03-0.04-0.120.45
Weighted avg. shares (diluted)217.50M216.90M216.50M188.88M108.02M
Balance sheet
Cash & equivalents$185.50M$129.00M$170.60M$163.20M$44.47M
Short-term investments—$0$325,000$82.33M$336.58M
Receivables$146.80M$153.40M$173.00M$153.25M$99.67M
Inventory$144.30M$190.80M$189.27M$133.81M$122.31M
Current assets$604.60M$576.90M$589.23M$585.93M$626.80M
PP&E, net$329.80M$339.10M$277.10M$198.75M$110.58M
Goodwill$1.05B$1.06B$2.14B$2.14B$142.70M
Intangibles$1.32B$1.41B$1.51B$1.59B$92.11M
Total assets$3.35B$3.44B$4.55B$4.55B$992.93M
Current liabilities$158.20M$174.00M$154.32M$145.47M$77.84M
Short-term debt$800.00M$19.30M$2.45M$900.00M—
Long-term debt$793.70M$874.80M$888.39M$885.44M$0
Total debt$1.59B$894.10M$890.84M$1.79B$0
Total liabilities$1.25B$1.37B$1.40B$1.42B$105.56M
Shareholders' equity$2.09B$2.07B$3.14B$3.13B$887.37M
Net debt$1.41B$765.10M$720.24M$1.62B-$44.47M
Shares outstanding217.70M217.00M217.04M216.25M107.80M
Cash flow statement
Operating cash flow$83.20M$58.20M$35.30M$41.03M$68.04M
Capital expenditure$51.30M$104.60M$111.40M$65.76M$24.43M
Free cash flow$31.90M-$46.40M-$76.10M-$24.73M$43.61M
Investing cash flow$70.50M-$99.20M-$29.30M$201.04M-$97.23M
Financing cash flow-$99.40M-$1.60M$1.90M-$118.08M$6.81M
Depreciation & amortization$116.30M$119.50M$116.70M$88.38M$23.69M
Stock-based compensation$13.40M$17.30M$13.80M$10.18M$7.15M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.